With over 1800m2 of manufacturing and laboratory space, company says it will be able to meet the demands of the market place for its products and stay ahead in diagnostic research and development
Monobind has moved into its state of the art new facility.
With this move it hopes to quickly complete its chemiluminescense line of products for thyroid endocrinologies, infectious diseases, cardiac monitoring, auto-immune diseases, tumour markers and so on.
With over 1800m2 of manufacturing and laboratory space, Monobind says it will be able to meet the demands of the market place for its products and effectively stay ahead in the fast changing environment of diagnostic research and development.
It has signed agreements with a German engineering company to make a chemiluminescense reader that will have all Monobind product applications software as part of the system design.
Also, it has concluded negotiations with a French manufacturer to launch a fully automated Elisa and Chemi microplate analyser under Monobind brand.
The automated analyser will be available in the market in April 2005, says the company.
